Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €121.51 EUR
Change Today +2.60 / 2.18%
Volume 14.0
As of 11:27 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BM8) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/23/15 - €127.00
52 Week Low
07/18/14 - €40.91
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

biomarin pharmaceutical inc (BM8) Details

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.

1,681 Employees
Last Reported Date: 03/2/15
Founded in 1996

biomarin pharmaceutical inc (BM8) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $480.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $528.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $417.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

biomarin pharmaceutical inc (BM8) Key Developments

BioMarin Pharmaceutical Inc. Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

BioMarin Pharmaceutical Inc. announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for the treatment of Duchenne Muscular Dystrophy amenable to exon 51 skipping. Validation of the MAA confirms that the submission is complete and starts the EMA's standard review process. Day 120 questions will be received on 22 October 2015, leading to a potential CHMP opinion in the first half of 2016 and a European Commission Decision by the third quarter of 2016. Drisapersen is an investigational antisense oligonucleotide drug candidate for the treatment of the large subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping. Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to approximately 13% of DMD patients. DMD is the most common fatal genetic disorder diagnosed in childhood, affecting approximately 1 in every 3,500 live male births. In Europe, it is estimated there are 23,000 boys and young men with Duchenne Muscular Dystrophy, and approximately 3,000 of those would be candidates for drisapersen. In BioMarin's commercial territories, approximately 85% of Duchenne patients are located outside of the United States, including Western Europe, Middle East, Eastern Europe, Latin America and Japan. Western Europe has the larges patient population among those areas, exceeding the United States by around 30%. It is estimated that DMD affects approximately 90,000 patients in BioMarin's commercial territories. Duchenne Muscular Dystrophy: Duchenne muscular dystrophy is a severely debilitating childhood neuromuscular disease caused by mutations in the dystrophin gene. This results in the absence or defect of the dystrophin protein, which is important in connecting the cytoskeleton of muscle fibers to the extracellular matrix. As a result, patients suffer from progressive loss of muscle strength, often rendering them wheelchair-bound before the age of 12 years. Respiratory and cardiac muscle can also be affected by the disease and most patients die in early adulthood due to respiratory and cardiac failure. Because the Duchenne gene is found on the X-chromosome, it primarily affects boys.

BioMarin Pharmaceutical Inc. Presents at Piper Jaffray Heartland Summit, Jun-23-2015

BioMarin Pharmaceutical Inc. Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: Jean-Jacques Bienaime, Chairman and Chief Executive Officer.

BioMarin Pharmaceutical Inc. - Special Call

To discuss Phase 2 results with BMN 111


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BM8:GR €121.51 EUR +2.60

BM8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $64.34 USD +1.42
Incyte Corp $104.21 USD +3.39
Jazz Pharmaceuticals PLC $176.07 USD +5.47
Momenta Pharmaceuticals Inc $22.81 USD +0.23
Vertex Pharmaceuticals Inc $123.48 USD +1.45
View Industry Companies

Industry Analysis


Industry Average

Valuation BM8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at